Addition of meloxicam to the treatment of bovine clinical mastitis results in a net economic benefit to the dairy farmer

Simple item page
dc.citation.issue4
dc.citation.volume101
dc.contributor.authorvan Soest FJS
dc.contributor.authorAbbeloos E
dc.contributor.authorMcDougall S
dc.contributor.authorHogeveen H
dc.coverage.spatialUnited States
dc.date.accessioned2024-02-04T20:45:55Z
dc.date.accessioned2024-07-25T06:43:48Z
dc.date.available2018-02-02
dc.date.available2024-02-04T20:45:55Z
dc.date.available2024-07-25T06:43:48Z
dc.date.issued2018-04
dc.description.abstractRecently, it has been shown that the addition of meloxicam to standard antimicrobial therapy for clinical mastitis (CM) improves the conception rate of dairy cows contracting CM in the first 120 d in milk. The objective of our study was to assess whether this improved reproduction through additional treatment with meloxicam would result in a positive net economic benefit for the farmer. We developed a stochastic bio-economic simulation model, in which a dairy cow with CM in the first 120 d in milk was simulated. Two scenarios were simulated in which CM cases were treated with meloxicam in conjunction with antimicrobial therapy or with antimicrobial therapy alone. The scenarios differed for conception rates (31% with meloxicam or 21% without meloxicam) and for the cost of CM treatment. Sensitivity analyses were undertaken for the biological and economic components of the model to assess the effects of a wide range of inputs on inferences about the cost effectiveness of meloxicam treatment. Model results showed an average net economic benefit of €42 per CM case per year in favor of the meloxicam scenario. Cows in the no-meloxicam treatment scenario had higher returns on milk production, lower costs upon calving, and reduced costs of treatment. However, these did not outweigh the savings associated with lower feed intake, reduced number of inseminations, and the reduced culling rate. The net economic benefit favoring meloxicam therapy was a consequence of the better reproductive performance in the meloxicam scenario in which cows had a shorter calving to conception interval (132 vs. 143 d), a shorter intercalving interval (405 vs. 416 d), and fewer inseminations per conception (2.9 vs. 3.7) compared with cows in the no-meloxicam treatment scenario. This resulted in a shorter lactation, hence a lower lactational milk production (8,441 vs. 8,517 kg per lactation) with lower feeding costs in the meloxicam group. A lower culling rate (12 vs. 25%) resulted in lower replacement costs in the meloxicam treatment scenario. All of the scenarios evaluated in the sensitivity analyses favored meloxicam treatment over no meloxicam. This study demonstrated that improvements in conception rate achieved by the use of meloxicam, as additional therapy for mild to moderate CM in the first 120 d in milk, have positive economic benefits. This inference remained true over a wide range of technical and economic inputs, demonstrating that use of meloxicam is likely to be cost effective across many production systems.
dc.description.confidentialfalse
dc.edition.editionApril 2018
dc.format.pagination3387-3397
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29398019
dc.identifier.citationvan Soest FJS, Abbeloos E, McDougall S, Hogeveen H. (2018). Addition of meloxicam to the treatment of bovine clinical mastitis results in a net economic benefit to the dairy farmer.. J Dairy Sci. 101. 4. (pp. 3387-3397).
dc.identifier.doi10.3168/jds.2017-12869
dc.identifier.eissn1525-3198
dc.identifier.elements-typejournal-article
dc.identifier.issn0022-0302
dc.identifier.piiS0022-0302(18)30028-6
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/70761
dc.languageeng
dc.publisherElsevier Inc and the Federation of Animal Science Societies (Fass) Inc on behalf of the American Dairy Science Association
dc.publisher.urihttps://www.journalofdairyscience.org/article/S0022-0302(18)30028-6/fulltext
dc.relation.isPartOfJ Dairy Sci
dc.rights(c) 2018 The Author/s
dc.rightsCC BY-NC-ND 3.0
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/
dc.subjectanimal health management
dc.subjectbovine clinical mastitis
dc.subjecteconomics
dc.subjectfertility
dc.subjectAnimals
dc.subjectAnti-Bacterial Agents
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectCattle
dc.subjectDairying
dc.subjectFemale
dc.subjectLactation
dc.subjectMastitis, Bovine
dc.subjectMeloxicam
dc.subjectMilk
dc.subjectModels, Economic
dc.subjectReproduction
dc.subjectStochastic Processes
dc.subjectThiazines
dc.subjectThiazoles
dc.titleAddition of meloxicam to the treatment of bovine clinical mastitis results in a net economic benefit to the dairy farmer
dc.typeJournal article
pubs.elements-id445641
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Published version
Size:
625.79 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Journal Articles